BAM
CAPR icon

Belpointe Asset Management’s Capricor Therapeutics CAPR Stock Holding History

Belpointe Asset Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,070
Closed -$8.73K – 994
2023
Q1 		$8.73K Hold
2,070
– – ﹤0.01% 2784
2022
Q4 		$7.99K Buy
+2,070
New +$9.88K ﹤0.01% 2729
2018
Q2 		– Sell
-7,229
Closed -$98K – 346
2018
Q1 		$98K Sell
7,229
-770
-10% -$13.4K 0.03% 335
2017
Q4 		$126K Sell
7,999
-225
-3% -$4.87K 0.03% 436
2017
Q3 		$249K Buy
+8,224
New +$98.4K 0.06% 354

Other funds holding CAPR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Belpointe Asset Management's CAPR Position: Q2 2023 in Review

Belpointe Asset Management sold out of Capricor Therapeutics (CAPR) in Q2 2023, closing a stake of 2,070 shares — an estimated $8.73K sold.

Belpointe Asset Management first reported a position in CAPR in Q3 2017 and held it in 5 quarters. The position peaked at $249K in Q3 2017. 32 funds tracked by Wall St. Rank hold CAPR as of Q2 2023.

  • Belpointe Asset Management reported no remaining Capricor Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 2,070 Capricor Therapeutics shares in Q2 2023, an estimated $8.73K.
  • Belpointe Asset Management first reported a position in Capricor Therapeutics in Q3 2017 and held it in 5 quarters.
  • Belpointe Asset Management's Capricor Therapeutics position peaked at $249K in Q3 2017.
  • 32 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.